Vocal Biomarkers Market

Vocal Biomarkers Market in terms of revenue was worth of USD 1901.1 Million in 2021 and is expected to reach USD 5131.8 Million in 2028, growing at a CAGR of 15.45% from 2021 to 2028.

Scope of Global Vocal Biomarker Market Report-

The Vocal Biomarker is a technique that allows machines to detect and understand human emotions by examining, recording, and finding raw sounds when people speak. Biomarkers in a person's voice are associated with disorders such as depression, arterial coronary heart disease, and anxiety. By decoding the tones of human voices into their underlying emotions in real-time, this technology enables applications and solutions, voice-powered devices to communicate on an emotional level, just like humans. Psychiatrists and clinical psychologists have been using subject / patient voice patterns for decades to research their personality traits and to benefit from medical and clinical investigations.

The technology sector in this market, has undergone tremendous changes in the last few years through technology. Based on technology, many players in the market have created services to check people's health status and many other ailments. This has created a great technology in the healthcare sector which is a way to save a lot of time and money for the patients. For this Product Type of technological advancement, market players have invested heavily in technology improvements. Also, some other players are working on product development which is a vital strategy for collaborating with leading companies and research institutes in a variety of fields, and healthcare is no exception. Hospitals and research institute jointly develop unique vocal biomarkers. Another leading player, Sonde Health Inc., introduced a voice-based technology platform that enables the diagnosis and monitoring of various conditions and diseases. The company partnered with the Massachusetts Institute of Technology (MIT) to license the technology. On July 8^th, 2022, PureTech Health Spinout, manufacturer of vocal biomarker technology, Sonde Health announced that it was collaborating with wireless technology company Qualcomm Technologies. The company announced that the partnership will integrate Sonde's machine learning vocal biomarker capabilities with Qualcomm's Snapdragon 888 and 778G 5G mobile platforms to bring health check-up and monitoring applications to mobile devices using the platform. Such collaboration and developments will lead to better solutions and more accurate results for patients. It will encourage researchers and organizations around the world to compile voice data for diagnosis and improve patient outcomes. This kind of new technology as well as the advancement of players are giving a big boost to the market.

A key factor driving the growth of the global Vocal Biomarkers Market is the growing demand for vocal biomarkers due to the increasing prevalence of Parkinson's disease and other diseases. Parkinson's disease (PD) is another common degenerative neurological problem after Alzheimer's disease. For example, according to the Parkinson's Foundation, about one million people in the US are living with Parkinson's disease (PD) and more than 10 million people worldwide are living with PD. Also, approximately 60,000 Americans are diagnosed with PD each year. Also, with the increasing popularity of technological advances and audio computing devices in everyday life, consistent models that can translate audio information into diagnostic tools for healthcare professionals will potentially provide cheaper and more accurate diagnoses. And vocal biomarkers have shown application in heart-patient remote health monitoring with test sounds of patients with coronary artery disease and to identify depression and stress. Moreover, vocal biomarkers also find applications to detect falsehoods. Thus, vocal biomarkers are used by the defense organization security agency when investing in criminals. Vocal biomarkers account for 38% of the analysis of false detection tests, according to international security agency officials, who said the demand for vocal biomarkers has increased over the forecast period.

However, significant errors in vocal characteristics and inaccuracies in word boundaries can hinder the growth of the global vocal biomarkers market. Nonetheless, research is being conducted to find disease biomarkers in the diagnosis of Parkinson's disease, brain damage, cognitive impairment, and respiratory diseases that offer a variety of opportunities in the global vocal biomarkers market.

North America is expected to dominate the global vocal biomarker market due to growing mental health disorders, the presence of major players, and technological advances in the region. For example, according to the Alzheimer's Association; in 2020, an estimated 5.8 million Americans aged 65 and over had Alzheimer's disease, which calls for faster research on biomarkers to detect Alzheimer's disease early. In addition, medical reimbursement policies and rising healthcare costs in the region contribute to market growth. Also, the U.S. According to the National Library of Medicine, a 39% increase in mortality is due to neurological disorders. According to the BrandEssence Market Survey, in 2019, there were 533,172 deaths due to neurological conditions across the region: 213,129 (40%) in men, and 320,043 (60%) in women.

Also, Europe is the second-dominating region in the global vocal biomarkers market due to increasing healthcare costs and growing awareness in the region. People in the European region are more aware of sound analysis using artificial intelligence (AI) for various applications of sound for diagnostic, risk prediction, and remote monitoring of various clinical outcomes and symptoms and for health-related purposes. Therefore, voice analysis using artificial intelligence (AI) such as voice biomarkers has opened up new opportunities for the healthcare sector in Europe. Thus, many companies are focusing on launching new voice analysis technology products.

Vocal Biomarkers Manufacturers

• Boston Technology Corporation
• EVOCAL Health
• Sonde Health
• Kintsugi
• AudEERING
• Sharecare
• Others

Vocal Biomarkers Market Segmentation-

By Product Type

• Frequency
• Amplitude
• Error Rate
• Voice Rise/fall time
• Phonation Time
• Others

By End-users

• Hospitals and Clinics
• Academic and Research
• Others

By Regional & Country Analysis:

• North America
• U.S.
• Canada
• Europe
• U.K.
• France
• Germany
• Italy
• Asia Pacific
• China
• Japan
• India
• Southeast Asia
• Latin America
• Brazil
• Mexico
• Middle East and Africa
• GCC
• Africa
• Rest of Middle East and Africa

Trends

A biomarker is an objectively measured and evaluated component that represents a biological or pathogenic processor that indicates a pharmacological response to a therapeutic intervention, which can be used as a surrogate marker of the clinical endpoint. In terms of sound, a vocal biomarker is a combination of features in an audio signal of a signature, feature, or voice that is related to a clinical outcome and can be used to monitor patients, diagnose a condition, or grade. For the severity of the disease stages or drug development.

The Major Trends Based on the Applications of Vocal Biomarkers can be as follows:

A) Parkinson’s Disease: -

Work on vocal biomarkers has so far been mainly in the field of neurodegenerative disorders, especially in Parkinson's disease, where noise disorders are very frequent (up to 89%) and where early changes in voice are expected to be used as early diagnostic biomarkers. Or a marker of disease progression and may one day undergo a state-of-the-art manual examination to guide the initiation of treatment or to evaluate the symptoms to monitor its effectiveness. These voice disorders are mainly related to pronunciation and pronunciation, including differences in pitch, loss of energy in the upper parts of the harmonic spectrum, and vague pronunciation of vowels and consonants, leading to reduced fluency. Although both patients and physicians ignored changes in voice in the early stages of the disease, objective measures showed changes in voice characteristics in 78% of patients with Parkinson's disease in the early stages.

B) Alzheimer’s Disease and Mild Cognitive Impairment: -

Alzheimer's disease and mild cognitive impairment subtle changes in voice and language can be seen many years before prodromal symptoms of Alzheimer's disease appear, and even in the early stages of mild cognitive impairment. Mild cognitive impairment and Alzheimer's disease have been shown to affect both verbal fluencies, resulting in the patient's speech hesitation and slow speech rate, or other defects, such as difficulty finding words, leading to confusion and frequent use of filler sounds (e.g., uh, um), semantic errors, uncertain terms, repetition, repetition, neologism, lexical and grammatical simplifications, as well as loss of semantic abilities in general. Discourse in Alzheimer's patients is characterized by low coherence, with unimaginable and irrelevant details. Changes in prosodic features (pitch variation and modulation, speech rhythm) have also been noticed and may affect the patient's emotional response. Voice features have the potential to be simple and non-invasive biomarkers for the early diagnosis of detention-related conditions.

C) Multiple Sclerosis and Rheumatoid Arthritis: -

Frequent comorbidities are a lack of voice and dysarthria in people with multiple sclerosis. It has also been suggested that long-term monitoring of voice features and vocal behaviors should be performed to indicate the best time to start treatment, such as deep brain stimulation, in people with multiple sclerosis. Some sound features have already been identified as top candidates for monitoring multiple sclerosis: pronunciation, respiration, and prosody. In people with arthritis, pathological changes in the larynx occur with the progression of the disease; Therefore, tracking voice quality features have already been shown to be useful for patient monitoring.

D) Mental Health and Monitoring Emotions: -

Stress is an established risk factor for tone symptoms. It has been shown that smartphone-based self-assessment stress is related to voice characteristics. A positive relationship between stress levels and the duration of verbal interactions has also been reported. Noise symptoms are more frequent in people with high levels of cortisol, which is common in patients with depression; therefore, voice features are used to detect the symptoms of depression or to estimate the severity of depression. The second dimension of the mail-frequency septum coefficient (MFCC) audio signal dissociation has been shown to differentiate patients with depression from control. Automated telephone systems have been successfully tested to evaluate biologically based vocal acoustics of depression severity and response to treatment, or to calculate post-traumatic stress disorder mental health scores. In addition to acoustic measures, the linguistic aspects of the voice are more likely to be affected by mental illness. In schizophrenia, discourse is inconsistent, manifested by an irrelevant flow of ideas, a meaningless relationship between words, or a digression from a subject. Situational speech is predominant in patients with bipolar and hysteric personality disorders. Recent systematic developments have also allowed the accuracy of emotion recognition to be matured enough for medical research to make it easier to Monitor patients to gather real-life information during visits or in clinical or epidemiological studies.

Some of the Emerging Trending Application are: -

E) Cardiometabolic and Cardiovascular Diseases: -

The Mayo Clinic team has identified several vocal features related to the history of coronary artery dis-age. In the case of diabetes, only one study has studied the vocal characteristics of people with Product Type 2 diabetes and non-diabetics showing differences between the 2 groups for many features (jitter, shimmer, smooth amplitude perturbation quotient, sound to harmonic ratio, relative average eccentricity, amplitude quotient). It has been shown that people with Product Type 2 diabetes have poor glycemic control or neuropathy, high stress, poor voice, and distinct voice quality, and the most common Product Type 2 diabetes pronounced symptoms are voice fatigue or hoarseness and hoarseness.

F) COVID-19 and Other Conditions with Respiratory Symptoms: -

Recently, significant research activities have emerged regarding the use of respiratory sounds (e.g., coughing, sneezing, and noise) as primary sources of information regarding COVID-19 pandemic. COVID-19 is a respiratory condition that affects breathing and sound and is accompanied by other symptoms, including dry cough, sore throat, excessive breathing, and specific breathing patterns. These are all symptoms that can make a patient's voice specific, make a recognizable voice signature, and enable training of algorithms to predict the presence of SARS-COV-2 infection or as a tool to grade disease severity. The results of vocal biomarkers are promising to help diagnose COVID-19 from Cambridge University (area under ROC curve, AUC = 80%) or more recently MIT scientists (AUC = 97%, based on cough recordings only). Other cough-based projects are aimed at developing a robot-based COVID-19 infection risk assessment system. Before launching such pre-screening tools on a large scale, future work should focus on the effect of age range or cultural background on the performance of the Cuff-based algorithm.

Report Analysis	Details
Historical data	2018 - 2021
Forecast Period	2022 - 2028
Market Size in 2021:	USD  1901.1 Million
Base year considered	2021
Forecast Period CAGR %:	15.45%
Market Size Expected in 2028:	USD 5131.8 Million
Tables, Charts & Figures:	175
Pages	300
Vocal Biomarkers Manufacturers	Boston Technology Corporation, EVOCAL Health, Sonde Health, Kintsugi, AudEERING, Sharecare, Others.
Segments Covered	By Technology, By Product, By Application
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa